Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | SCN4A | P35499 | 2/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | TDO2 | P48775 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3289611 | 0.92 | SLC6A4 (0.52) | SLC6A4SCN4ASLC6A2SLC6A3TACR1 | |
| SCHEMBL272604 | 0.85 | EPHX1 (0.61) | SLC6A4SCN4ASLC6A2SLC6A3CYP1A2 | |
| SCHEMBL3451169 | 0.85 | EPHX1 (0.61) | SLC6A4SCN4ASLC6A2SLC6A3CYP1A2 | |
| SCHEMBL468022 | 0.85 | EPHX1 (0.61) | SLC6A4SCN4ASLC6A2SLC6A3CYP1A2 | |
| SCHEMBL5551844 | 0.83 | SLC6A2 (0.53) | SLC6A4SCN4ASLC6A2SLC6A3TACR1 | |
| Hydrochloric Acid SCHEMBL28839661 | 0.83 | EPHX1 (0.58) | SLC6A4SLC6A2SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL9322166 | 0.82 | MAOB (0.50) | SLC6A4SCN4ASLC6A2SLC6A3CYP1A2 | |
| SCHEMBL17887234 | 0.82 | ACP3 (0.51) | SLC6A4SLC6A2SLC6A3CHRNB2CHRNA4 | |
| SCHEMBL9194002 | 0.80 | HTR2A (0.52) | SLC6A4SLC6A2SLC6A3TACR1CYP1A2 | |
| SCHEMBL8068540 | 0.80 | HTR2A (0.52) | SLC6A4SLC6A2SLC6A3TACR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4297282-A | REACTING AN A-METHYL-B-ACYLTHIOPROPIONIC ACID WITH AN OPTICALLY ACTIVE ARYLALKYL PRIMARY AMINE; CRYSTALLIZATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-10-27 | — | — | US | claimed |
| JP-56007756-A | — | — | None | — | — | JP | disclosed |
| US-6894190-B2 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-05-17 | — | — | US | disclosed |
| US-20030232886-A1 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-12-18 | — | — | US | disclosed |
| US-6653507-B2 | Useful intermediate compound of pharmaceuticals for urinary incontinence | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-11-25 | — | — | US | disclosed |
| US-20020143212-A1 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-10-03 | — | — | US | disclosed |
| US-6403832-B1 | MIXING ACID WITH AMINE, PRECIPITATING SALT, AND FILTERING; GOOD OPTICAL PURITY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-1074539-A2 | Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-02-07 | — | — | EP | disclosed |
| US-6017910-A | PCP receptor ligands and the use thereof | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 2000-01-25 | — | — | US | disclosed |
| US-5688789-A | TREATMENT OR PREVENTION OF NEURONAL LOSS IN ISCHEMIA, HYPOXIA, BRAIN OR SPINAL CORD TRAUMA, TREATMENT OF ALZHEIMER'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, HUNTINGTON'S DISEASE, DOWN'S SYNDROME | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1997-11-18 | — | — | US | disclosed |
| US-5508401-A | N-METHYL-D-ASPARTATE ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| EP-0573548-B1 | NEUROPROTECTANT AGENTS | AMERICAN HOME PROD (US) | 1995-07-12 | — | — | EP | disclosed |
| EP-0587670-A4 | PCP RECEPTOR LIGANDS AND THE USE THEREOF. | OREGON STATE (US) | 1995-02-01 | — | — | EP | disclosed |
| EP-0587670-A1 | PCP RECEPTOR LIGANDS AND THE USE THEREOF | STATE OF OREGON, acting through OREGON STATE BOARD OF HIGHER EDUCATION, acting for OREGON HEALTH SC. UNIV. AND UNIV. OF OREGON (US) | 1994-03-23 | — | — | EP | disclosed |
| WO-1992019621-A1 | PCP RECEPTOR LIGANDS AND THE USE THEREOF | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE, OREGON (US) | 1992-11-12 | — | — | WO | disclosed |
| EP-0092194-B1 | METHOD OF OBTAINING OPTICALLY ACTIVE HALF ESTERS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-07-08 | — | — | EP | disclosed |
| US-4411836-A | HEATING IN PRESENCE OF FATTY OR AROMATIC ACID SALT OR TERTIARY AMINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-10-25 | — | — | US | disclosed |
| US-4297282-A | REACTING AN A-METHYL-B-ACYLTHIOPROPIONIC ACID WITH AN OPTICALLY ACTIVE ARYLALKYL PRIMARY AMINE; CRYSTALLIZATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-10-27 | — | — | US | disclosed |
| JP-S567756-A | PREPARATION OF OPTICALLY ACTIVE D-ALPHA-METHYL-BETA- MERCAPTOPROPIONIC ACID DERIVATIVE | SUMITOMO CHEM CO LTD | 1981-01-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232886-A1 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | ALDH1A2, CYP8B1, CYP11B2 | SLC6A4 1024/4885SCN4A 1299/4885SLC6A2 859/4885 |
| US-20020143212-A1 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | ALDH1A2, ALDH7A1, ALDH18A1 | SLC6A4 1142/4885SCN4A 461/4885SLC6A2 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.